Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemagglutinin H3 is a **trimeric glycoprotein** found on the surface of the Influenza A virus, particularly the H3N2 subtype. It facilitates **viral entry into host cells** by binding to sialic acid–containing receptors on the cell surface and mediating the fusion of viral and host membranes after endocytosis. This dual function makes it essential for infectivity and pathogenicity. The HA protein is synthesized as a single precursor (HA0), which must be cleaved into HA1 and HA2 subunits for activation. HA is a major target of neutralizing antibodies, which block viral attachment and/or fusion. The H3 subtype is a major cause of **seasonal influenza** in humans and is associated with significant morbidity and mortality, especially among vulnerable populations. **Antigenic drift** in HA H3 enables the virus to evade preexisting immunity, necessitating frequent updates of influenza vaccines.
Blocking viral attachment to host receptors (by antibodies); Inhibiting conformational changes required for membrane fusion (by antibodies)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A virus hemagglutinin protein H3 (Hemagglutinin H3 of Influenza A virus) (HA (specifically H3 subtype)).